Skip to main content

Grafa News and Videos — Page 1605

Latest

Grafa

Palvella Therapeutics reveals positive Phase 3 SELVA results and upsized $216M financing

Palvella Therapeutics (NASDAQ:PVLA) reported transformative full-year 2025 financial results and a significant corporate update on March 31, 2026, headlined by the successful clinical validation of its lead rare disease program.

Read more: Palvella Therapeutics reveals positive Phase 3 SELVA results and upsized $216M financing

GET YOUR GRAFA EDGE NOW

We'll switch on a 30-day Edge trial as a welcome gift